《大行報告》大華繼顯降舜宇(02382.HK)目標價至63元 出貨指引較預期弱
大華繼顯發表報告下調舜宇(02382.HK)目標價,由77.1元降至63元,維持「買入」評級。
報告指,舜宇去年下半年純利僅及盈警下限的6.63億元人民幣,縱使智能手機業務清晰的復甦趨勢仍然存在,今年交付及毛利率指引均遜預期。該行料舜宇股價波動,但智能手機交付改善及華為新產品推出,短期內或為股價提供關鍵支持。
該行下調對舜宇今明兩年盈利預測22%至23%,至分別18.81億及27.8億元人民幣,以反映對手機鏡頭、手機鏡頭模組及車用鏡頭等產品交付與收入假設下調,手機鏡頭模組平均售價假設下調,以及手機鏡頭與手機鏡頭模組產品毛利率假設下調,但部分由光學部件平均售價假設上調抵銷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.